News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
456,916 Results
Type
Article (22040)
Company Profile (159)
Press Release (434717)
Section
Business (148361)
Career Advice (1170)
Deals (27212)
Drug Delivery (93)
Drug Development (58850)
Employer Resources (95)
FDA (9772)
Job Trends (9983)
News (248554)
Policy (21506)
Tag
Academia (945)
Alliances (35222)
Alzheimer's disease (745)
Approvals (9737)
Artificial intelligence (97)
Bankruptcy (227)
Best Places to Work (7195)
Biotechnology (81)
Breast cancer (103)
Cancer (819)
Cardiovascular disease (74)
Career advice (969)
Cell therapy (142)
Clinical research (48278)
Collaboration (287)
Compensation (140)
COVID-19 (1322)
C-suite (90)
Data (904)
Diabetes (116)
Diagnostics (3273)
Drug pricing (96)
Earnings (61119)
Employer resources (87)
Events (71487)
Executive appointments (291)
FDA (10136)
Funding (252)
Gene therapy (109)
GLP-1 (525)
Government (2046)
Healthcare (9395)
Infectious disease (1380)
Inflammatory bowel disease (77)
Interviews (156)
IPO (11987)
Job creations (3047)
Job search strategy (882)
Layoffs (299)
Legal (5654)
Lung cancer (113)
Manufacturing (156)
Medical device (5383)
Medtech (5387)
Mergers & acquisitions (15327)
Metabolic disorders (375)
Neuroscience (952)
NextGen Class of 2024 (3432)
Non-profit (1473)
Northern California (1027)
Obesity (236)
Opinion (179)
Patents (81)
People (43713)
Pharmaceutical (81)
Phase I (14960)
Phase II (20795)
Phase III (16313)
Pipeline (413)
Policy (73)
Postmarket research (1859)
Preclinical (5541)
Radiopharmaceuticals (189)
Rare diseases (173)
Real estate (4241)
Regulatory (14668)
Research institute (997)
Resumes & cover letters (177)
Southern California (899)
Startups (2480)
United States (9308)
Vaccines (238)
Weight loss (192)
Date
Today (76)
Last 7 days (452)
Last 30 days (1926)
Last 365 days (23716)
2024 (23053)
2023 (27020)
2022 (35764)
2021 (37951)
2020 (35284)
2019 (27893)
2018 (21424)
2017 (22405)
2016 (21164)
2015 (25311)
2014 (20573)
2013 (17306)
2012 (18631)
2011 (19163)
2010 (18163)
Location
Africa (507)
Arizona (92)
Asia (29739)
Australia (3944)
California (2275)
Canada (1129)
China (189)
Colorado (108)
Connecticut (110)
Europe (61325)
Florida (318)
Illinois (212)
Indiana (155)
Maryland (301)
Massachusetts (1916)
Michigan (98)
Minnesota (159)
New Jersey (822)
New York (665)
North Carolina (513)
Northern California (1027)
Ohio (90)
Pennsylvania (525)
South America (757)
Southern California (899)
Texas (334)
Washington State (216)
456,916 Results for "nutra pharma corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Protect Pharmaceutical Corp. Issues Corporate Update
Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: “July 1, 2024 Dear Shareholders: The Company’s PCAOB audit for the fiscal year of 2023 is near completion.
July 1, 2024
·
4 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
NervGen Pharma Grants Stock Options.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000
June 7, 2024
·
1 min read
Business
FSD Pharma provides Corporate Update
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.
June 28, 2024
·
10 min read
News
SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems
July 16, 2024
·
2 min read
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
·
9 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
NervGen Pharma Announces Results of Annual General Meeting of Shareholders..
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders (“AGM”) held on June 4, 2024.
June 5, 2024
·
6 min read
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the development of a new drug candidate, NVG-300
June 25, 2024
·
7 min read
1 of 45,692
Next